Amneal Pharmaceuticals to acquire Kashiv BioSciences in strategic biosimilar expansion

Amneal Pharmaceuticals (NASDAQ:AMRX) and Kashiv BioSciences announced today that they have entered into a definitive agreement for Amneal to acquire Kashiv.

The transaction, expected to close in the second half of 2026, marks a major step in Amneal’s strategy to bolster its presence in the high-growth biosimilar market.

The acquisition combines Kashiv’s specialized expertise in the development and manufacturing of complex biosimilars with Amneal’s massive commercial infrastructure and distribution scale.

Based in Piscataway, New Jersey, with additional operations in India, Kashiv brings a robust pipeline of biological products designed to offer affordable alternatives to high-cost specialty drugs.

Bridgewater, New Jersey-based Amneal, already one of the largest affordable medicine providers in the United States, expects the integration to create a vertically integrated platform.

By controlling the process from initial development through to commercialization, the combined entity aims to lower production costs and expand patient access to critical therapies globally.

The deal is subject to the approval of Amneal shareholders, the receipt of necessary regulatory clearances, and other customary closing conditions.